Cheryl Maley

Cheryl has over 25 years of experience in the pharmaceutical industry, including 20 years in leadership roles at well-known and leading organisations, including Novartis and AbbVie/Abbott. Her roles include nine years at Novartis in senior commercial and executive roles and various sales and marketing positions with AbbVie, Servier Laboratories, and Wyeth Pharmaceuticals. Cheryl has had extensive experience in leading pharmaceutical innovation, marketing, commercialisation and delivering business growth across Australia, Asia, and international markets. She has a strong commercial background with a proven record in successful product launches and patient access and reimbursement to innovative medicines. During her nine-year career at Novartis, Cheryl held a number of senior leadership positions where she had responsibility for new products, commercialisation and strategy, as well as reimbursement matters. Cheryl was Country Head and President of Novartis Philippines, where she was responsible for the Pharmaceutical Division and oversaw the cross-divisional leadership team, including the Oncology, Sandoz and Alcon business units. In her most recent Novartis role as General Manager, Oncology, Australia and New Zealand (ANZ), Cheryl led Novartis’ oncology division in the ANZ region, with P&L responsibility and oversight of all business functions, including medical, commercial/sales, finance, operations, legal, market access, and compliance. In this role, Cheryl oversaw the successful launch of Australia’s first CAR T cell therapy, Kymriah®, for the treatment of B-cell acute lymphoblastic leukemia, one of Novartis’ top 20 medicines by sales in 2022. Cheryl has most recently been serving as the Acting CEO and Strategic Advisor at Biointelect, a firm that specialises in strategic planning and commercialisation for the biopharmaceutical and medical device sector. During this time, she has supported a number of research institutions and biotech companies to achieve their goals of growth, transformation and successful commercialisation.